Individualization of attention-deficit/hyperactivity disorder treatment: pharmacotherapy considerations by age and co-occurring conditions
| Autor: | Paul E.A. Glaser, Joshua Wilson, Greg Mattingly, Leticia Ugarte |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
Adolescent medicine.medical_treatment Comorbidity 03 medical and health sciences Young Adult 0302 clinical medicine Neurodevelopmental disorder Quality of life (healthcare) Pharmacotherapy mental disorders medicine Attention deficit hyperactivity disorder Humans 0501 psychology and cognitive sciences Drug Dosage Calculations Autistic Disorder Psychiatry Child Depression (differential diagnoses) business.industry Depression 05 social sciences Age Factors medicine.disease Substance abuse Stimulant Psychiatry and Mental health Attention Deficit Disorder with Hyperactivity Autism Central Nervous System Stimulants Neurology (clinical) business 030217 neurology & neurosurgery 050104 developmental & child psychology |
| Zdroj: | CNS spectrums. 26(3) |
| ISSN: | 1092-8529 |
| Popis: | Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder that manifests in childhood and can persist into adolescence and adulthood. Impairments associated with ADHD can impact quality of life, social interactions, and increase the risk of morbidity and mortality; however, for many patients, effective treatment can lessen these effects. Pharmacotherapy with stimulants or nonstimulants is recommended in conjunction with psychosocial therapy for most patients. Determining the optimal pharmacotherapy can be complex, and the clinician needs to consider many factors such as the patient’s age, comorbidities, and lifestyle. Furthermore, the needs of the patient with ADHD will change over time, with specific challenges to consider at each stage of life. A variety of Food and Drug Administration (FDA)-approved stimulant and nonstimulant formulations are available with different modes of delivery and durations of effect. This armamentarium of ADHD medications can be used to individualize ADHD treatment for each patient’s needs. This article combines current information from the literature and the first-hand experience of the authors to provide guidance on ADHD treatment options for patients of different ages and for some of the more common comorbidities. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|